Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853097 | 0.97 | KMT2A (0.38) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL14827686 | 0.97 | KMT2A (0.38) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL14825982 | 0.84 | KMT2A (0.48) | KMT2AMEN1CYP3A4ALOX15DPP7 | |
| SCHEMBL14827685 | 0.81 | KMT2A (0.53) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL14827709 | 0.81 | KMT2A (0.53) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL14825983 | 0.79 | KMT2A (0.38) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL14826005 | 0.79 | KMT2A (0.38) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL14826009 | 0.79 | KMT2A (0.38) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL16706215 | 0.79 | KMT2A (0.38) | KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL16706212 | 0.77 | KMT2A (0.36) | KMT2AMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013052148-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | GGPS1, FNTA, GNPAT | KMT2A 4082/4885MEN1 2850/4885CYP3A4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.